Projects

RNDr. Miroslava Matúšková, PhD.
Head of department

International

Current
  • Nanobiotechnologies for Innovative Therapeutic Approaches for Cancer
    Program: Horizon Europe
    Duration: 1. 11. 2023 – 31. 10. 2028
  • International networking on in vitro colon models simulating gut microbiota mediated interactions
    Program: COST
    Duration: 9. 10. 2024 – 8. 10. 2028
Finished
  • Resistance under treatment in breast cancer
    Program: ERANET
    Duration: 1. 8. 2020 – 31. 5. 2024
  • A4L_ACTIONS POst-Transcriptional Oncogenic Modifications And their Consequences
    Program: Other
    Duration: 1. 3. 2023 – 29. 2. 2024
  • Strategies to strengthen scientific excellence and innovation capacity for early diagnosis of gastrointestinal cancer
    Program: Horizon 2020
    Duration: 1. 10. 2019 – 30. 6. 2023
  • Establishing an algorithm for the early diagnosis and follow-up of patients with pancreatic neuroendocrine tumors
    Program: ERANET
    Duration: 1. 9. 2019 – 31. 3. 2023
  • Targeted combination therapy of colon cancer with therapeutic gene/drug loaded novel dendritic nanocarriers
    Program: Bilateral - other
    Duration: 3. 9. 2018 – 30. 11. 2022
  • Innovative Nanopharmaceuticals: Targeting Breast Cancer Stem Cells by a Novel Combination of Epigenetic and Anticancer Drugs with Gene Therapy
    Program: ERANET
    Duration: 1. 1. 2017 – 30. 6. 2021

National

Current
  • Carbonic anhydrase I and cancer cell tumorigenicity
    Program: VEGA
    Duration: 1. 1. 2025 – 31. 12. 2028
  • Identification of novel biomarkers linked to the relapse of metastatic colorectal cancer after metastasectomy
    Program: SRDA
    Duration: 1. 7. 2022 – 30. 6. 2026
Finished
  • Identification of new treatment options in refractory testicular germ cell tumors
    Program: SRDA
    Duration: 1. 7. 2021 – 30. 6. 2025
  • Molecular mechanisms of trialkyl-/triaryltin isothiocyanates\' and carboxylates\' antitumour properties - novel ligands of nuclear retinoid X receptors in rat mammary gland carcinomas and human tumour cell lines
    Program: SRDA
    Duration: 1. 7. 2021 – 30. 6. 2025
  • Identification of potential therapeutic targets associated with cisplatin resistance in yolk sac tumors
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • The role of mitochondria in progression of colorectal cancer
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • Inhibition of Carbonic Anhydrase IX (CA IX) Circumventing Cisplatin Resistance in Refractory Testicular Germ Cell Tumours
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2023
  • Identification of chemoresistant cell populations with metastatic potential in colorectal carcinoma
    Program: VEGA
    Duration: 1. 1. 2019 – 31. 12. 2022
  • Markers overlapping chemoresistance and metastatic potential in colorectal cancer - aldehyde dehydrogenase and its clinical relevance
    Program: Other projects
    Duration: 1. 11. 2019 – 31. 12. 2022
  • TArgetiNg Dna mEthylation by epigenetic editing and its implementation into personalised diagnostics and therapy of uveal Melanoma
    Program: SRDA
    Duration: 1. 8. 2018 – 31. 12. 2022
  • Molecular biomarkers of relapse in seminoma clinical stage I patients
    Program: Other projects
    Duration: 1. 10. 2019 – 21. 12. 2022
  • Mechanism of the mesenchymal stromal cell-induced tolerance to antitumor treatment and targeted therapeutic intervention in the breast cancer cells
    Program: SRDA
    Duration: 1. 7. 2017 – 31. 12. 2021
  • Identification and validation of signalling pathways associated with circulating tumor cells in breast cancer
    Program: SRDA
    Duration: 1. 7. 2017 – 30. 6. 2021
  • The role of ALDH1 in chemoresistance of cancer cells
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2020
  • Role of Stress Response Induced in Mesenchymal Stromal Cells in Extrinsic Drug Resistance of Human Tumor Cells
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2018
  • Xenografts and organoids derived from primary tumour tissues
    Program: Other projects
    Duration: 1. 6. 2018 – 30. 11. 2018
  • Mechanisms of interactions and bystander effect mediated by mesenchymal stromal cells expressing prodrug-converting genes on tumour stem cells
    Program: SRDA
    Duration: 1. 10. 2013 – 30. 9. 2017
  • Cytotoxic Effect of Engineered Mesenchymal Stromal Cells on Human Chemoresistant Tumour Cells and Cancer Stem Cells
    Program: VEGA
    Duration: 1. 1. 2013 – 31. 12. 2016
  • Targeted Augmented Cellular Therapy against Tumor Initiating and Chemoresistant Cells
    Program: SRDA
    Duration: 1. 7. 2012 – 31. 12. 2015
  • Molecular mechanisms of tumor-driven mesenchymal stromal cells‘ differentiation
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 12. 2014
  • Chemoresistance abrogation in human cancer stem cells by inhibition of ALDH1A1 enzyme
    Program: Other projects
    Duration: 1. 7. 2012 – 30. 6. 2013
  • Study of interactions between tumour cells and mesenchymal stem cells carrying suicide genes.
    Program: VEGA
    Duration: 1. 1. 2010 – 31. 12. 2012
  • Gene-cell therapy of cancer using a self-inactivating - retroviral vectors inducibly expressing tumour necrosis factor alpha in human mesenchymal stem cells
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2011
  • Human mesenchymal stem cells as cytoreagents for metastasis-targeted therapy
    Program: SRDA
    Duration: 1. 6. 2008 – 30. 6. 2011
  • Implementation of histology and molecular-biology methods in the tumor heterogenity analysis
    Program: Intra-constitutional
    Duration: 1. 1. 2010 – 31. 12. 2010
  • Interaction of human adipose-tissue derived mesenchymal stem cells with human cancer cells
    Program: VEGA
    Duration: 1. 1. 2007 – 31. 12. 2009
Employees